CDIO vs. SAI, MLGO, TRIB, OCX, BMRA, MYMD, MCAG, AWH, ICCC, and ABIO
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include SAI.TECH Global (SAI), MicroAlgo (MLGO), Trinity Biotech (TRIB), OncoCyte (OCX), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), Mountain Crest Acquisition Corp. V (MCAG), Aspira Women's Health (AWH), ImmuCell (ICCC), and ARCA biopharma (ABIO).
Cardio Diagnostics (NASDAQ:CDIO) and SAI.TECH Global (NASDAQ:SAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
SAI.TECH Global has higher revenue and earnings than Cardio Diagnostics.
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 0.2% of SAI.TECH Global shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 1.4% of SAI.TECH Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cardio Diagnostics currently has a consensus price target of $1.35, suggesting a potential upside of 84.93%. Given Cardio Diagnostics' higher probable upside, equities analysts plainly believe Cardio Diagnostics is more favorable than SAI.TECH Global.
In the previous week, Cardio Diagnostics had 2 more articles in the media than SAI.TECH Global. MarketBeat recorded 3 mentions for Cardio Diagnostics and 1 mentions for SAI.TECH Global. Cardio Diagnostics' average media sentiment score of 0.00 beat SAI.TECH Global's score of -0.42 indicating that Cardio Diagnostics is being referred to more favorably in the media.
SAI.TECH Global has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -34,911.87%. SAI.TECH Global's return on equity of 0.00% beat Cardio Diagnostics' return on equity.
Cardio Diagnostics has a beta of 5.3, suggesting that its share price is 430% more volatile than the S&P 500. Comparatively, SAI.TECH Global has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.
Cardio Diagnostics received 2 more outperform votes than SAI.TECH Global when rated by MarketBeat users.
Summary
Cardio Diagnostics beats SAI.TECH Global on 9 of the 14 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardio Diagnostics Competitors List
Related Companies and Tools
